Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

Amerikaanse aandelen« Terug naar discussie overzicht

intercloud--icld

429 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 22 »» | Laatste | Omlaag ↓
  1. [verwijderd] 23 januari 2016 17:31
    quote:

    Jager63 schreef op 21 januari 2016 22:41:

    Probeer eerst maar eens een paar duizend stuks te verkopen. De order moet eerst uitgevoerd zijn, voordat je een kooporder kunt doorgeven. Lukt mij niet, zoals ik zou willen.
    eigenlijk kan en mag dit helemaal niet
    Je bent baas over je eigen centen
    Mits er geen cash beschikbaar is
  2. [verwijderd] 3 februari 2016 19:48
    Analysts Review Valeant Pharmaceuticals Intl Inc (VRX) and Synthetic Biologics Inc (SYN) Following Recent Developments
    SHARE ON:
    Kate George, Editor — February 3, 2016, 9:33 AM EDT
    There’s never a dull moment in the biotechnology sector as analysts weigh in on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in light of a congressional memo exploring pricing practices and Synthetic Biologics Inc (NYSEMKT:SYN) after the company announced the termination of a drug license.

    Valeant Pharmaceuticals Intl Inc

    Irina Rivkind Koffler of Mizuho weighed in on Valeant after the House Oversight Committee released a memo yesterday explaining Valeant’s drug pricing strategy. The company came under scrutiny in October for its drug pricing practices after the company acquired two heart drugs, Isuprel and Nitropress, and hiked up the prices.

    The analyst believes Congresses’ memo “paints a damning picture of an organization whose unified goal was to generate profit, rather focus on patients.” She continues, “Furthermore, the memo alleges that the company was keenly aware of its actions and tried to obfuscate its pricing actions via PR initiatives.” As a result, the analyst expects VRX shares to remain “highly volatile” this week.

    Koffler also explains that CEO Mike Pearson is unlikely to return to the company. Pearson has been out on medical leave with pneumonia complications since December. However, Congresses’ memo alleges that CFO Howard Schiller and Pearson were aware of the pricing discrepancies due to information exchanged in a conference call last year. Koffler explains, “We think that the company may need to clarify these discrepancies and believe that investors and large shareholders could be unforgiving if management’s credibility is in question.” Due to the disclosures in the report, Koffler finds it unlikely that Pearson will return to his position.

    Ultimately, Koffler reiterates a Neutral rating on Valeant with an unchanged price target of $112 in light of future uncertainty and stock volatility surrounding Congresses’ memo on the company’s drug pricing practices.

    Koffler has a 59% success rate recommending stocks with a 34.8% average return per rating. According to TipRanks, 9 analysts are currently bullish on the stock while 8 remain on the sidelines. The average 12-month price target between these 17 analysts is $156.64, marking a 71% potential upside from current levels.
429 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 22 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.